| 1 | Microenvironmental Regulation of Tumor Progression and Metastasis | 2013 | 7,351 |
| 2 | Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors | 1984 | 7,097 |
| 3 | Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies | 2006 | 4,953 |
| 4 | The Biology and Management of Non-Small Cell Lung Cancer | 2018 | 4,386 |
| 5 | Inflammageing: Chronic Inflammation in Ageing, Cardiovascular Disease, and Frailty | 2018 | 3,444 |
| 6 | Quantitative Assessment of Antimalarial Activity in Vitro by a Semiautomated Microdilution Technique. | 1979 | 2,445 |
| 7 | A Comprehensive Map of Molecular Drug Targets | 2017 | 2,214 |
| 8 | Unresponsiveness of Colon Cancer to BRAF(V600E) Inhibition Through Feedback Activation of EGFR | 2012 | 1,958 |
| 9 | EZH2 Inhibition as a Therapeutic Strategy for Lymphoma With EZH2-Activating Mutations | 2012 | 1,736 |
| 10 | Endometriosis: Pathogenesis and Treatment | 2014 | 1,703 |
| 11 | The Epidemiology of Urinary Tract Infection | 2010 | 1,447 |
| 12 | Local Clearance of Senescent Cells Attenuates the Development of Post-Traumatic Osteoarthritis and Creates a Pro-Regenerative Environment | 2017 | 1,446 |
| 13 | A Bayesian Neural Network Method for Adverse Drug Reaction Signal Generation | 1998 | 1,410 |
| 14 | Induced Pluripotent Stem Cell Technology: A Decade of Progress | 2017 | 1,402 |
| 15 | Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin | 2001 | 1,379 |
| 16 | Metformin Improves Healthspan and Lifespan in Mice | 2013 | 1,355 |
| 17 | Recommendations for Presenting Analyses of Effect Modification and Interaction. | 2012 | 1,327 |
| 18 | The Role of Synovitis in Pathophysiology and Clinical Symptoms of Osteoarthritis | 2010 | 1,309 |
| 19 | Spectral Studies of Drug Interaction With Hepatic Microsomal Cytochrome | 1967 | 1,303 |
| 20 | Epithelial Cell Cycle Arrest in G2/M Mediates Kidney Fibrosis After Injury | 2010 | 1,275 |
| 21 | GLP-1 Receptor Agonists for Individualized Treatment of Type 2 Diabetes Mellitus | 2012 | 1,273 |
| 22 | Continued Improvement in Survival in Multiple Myeloma: Changes in Early Mortality and Outcomes in Older Patients | 2014 | 1,265 |
| 23 | Mechanisms of Action of Hydroxychloroquine and Chloroquine: Implications for Rheumatology | 2020 | 1,235 |
| 24 | Metformin—Mode of Action and Clinical Implications for Diabetes and Cancer | 2014 | 1,233 |
| 25 | A Phase 1 Evaluation of the Pharmacokinetic/Pharmacodynamic Interaction of the Anti-Malarial Agents KAF156 and Piperaquine | 2018 | 1,168 |
| 26 | Spiroindolones, a Potent Compound Class for the Treatment of Malaria | 2010 | 1,156 |
| 27 | Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory Concentration. | 1987 | 1,135 |
| 28 | A Tutorial on Interaction | 2014 | 1,092 |
| 29 | Mapping Human Microbiome Drug Metabolism by Gut Bacteria and Their Genes | 2019 | 1,090 |
| 30 | Herb-Drug Interactions | 2000 | 1,089 |
| 31 | Towards the Sustainable Discovery and Development of New Antibiotics | 2021 | 1,069 |
| 32 | Tau-Targeting Therapies for Alzheimer Disease | 2018 | 1,029 |
| 33 | Artesunate Versus Quinine for Treatment of Severe Falciparum Malaria: A Randomised Trial | 2005 | 1,028 |
| 34 | Analysis of Drug Combinations: Current Methodological Landscape | 2015 | 1,017 |
| 35 | Systematic Overview of Warfarin and Its Drug and Food Interactions | 2005 | 1,004 |
| 36 | Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both | 2017 | 988 |
| 37 | Platelet Biology and Functions: New Concepts and Clinical Perspectives | 2019 | 977 |
| 38 | ZNRF3 Promotes Wnt Receptor Turnover in an R-Spondin-Sensitive Manner | 2012 | 940 |
| 39 | Artemisinins Target the SERCA of Plasmodium falciparum | 2003 | 936 |
| 40 | Drug-Drug Interactions for UDP-Glucuronosyltransferase Substrates: A Pharmacokinetic Explanation for Typically Observed Low Exposure (AUCi/AUC) Ratios. | 2004 | 932 |
| 41 | Artesunate Versus Quinine in the Treatment of Severe Falciparum Malaria in African Children (AQUAMAT): An Open-Label, Randomised Trial | 2010 | 921 |
| 42 | Adverse Events and Complications Associated With Intravitreal Injection of Anti-VEGF Agents: A Review of Literature | 2013 | 920 |
| 43 | Quinine, an Old Anti-Malarial Drug in a Modern World: Role in the Treatment of Malaria | 2011 | 902 |
| 44 | Mechanisms of Drug Combinations: Interaction and Network Perspectives | 2009 | 901 |
| 45 | Integration of the Drug–Gene Interaction Database (DGIdb 4.0) With Open Crowdsource Efforts | 2021 | 885 |
| 46 | The SGLT2 Inhibitor Empagliflozin in Patients Hospitalized for Acute Heart Failure: A Multinational Randomized Trial | 2022 | 885 |
| 47 | A Method for Assessing Drug Therapy Appropriateness | 1992 | 878 |
| 48 | Predicting in Vivo Drug Interactions From in Vitro Drug Discovery Data | 2005 | 870 |
| 49 | Use of Prescription and Over-the-Counter Medications and Dietary Supplements Among Older Adults in the United States | 2008 | 870 |
| 50 | The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis | 2011 | 864 |
| 51 | Two-Year Effects of Semaglutide in Adults With Overweight or Obesity: The STEP 5 Trial | 2022 | 864 |
| 52 | Qinghaosu (Artemisinin): The Price of Success | 2008 | 854 |
| 53 | The Role of Intestinal P-Glycoprotein in the Interaction of Digoxin and Rifampin | 1999 | 854 |
| 54 | Anti-Diabetic Drugs Inhibit Obesity-Linked Phosphorylation of PPARγ by Cdk5 | 2010 | 851 |
| 55 | Interaction of Drugs With Bovine and Human Serum Albumin | 2002 | 850 |
| 56 | Metal Chelation and Inhibition of Bacterial Growth in Tissue Abscesses | 2008 | 831 |
| 57 | Crystal Structure Analysis of Warfarin Binding to Human Serum Albumin: Anatomy OF DRUG SITE I | 2001 | 815 |
| 58 | Cytochrome P4502C9: An Enzyme of Major Importance in Human Drug Metabolism | 1998 | 808 |
| 59 | Assessment and Management of Blood-Pressure Variability | 2013 | 808 |
| 60 | Data-Driven Prediction of Drug Effects and Interactions | 2012 | 800 |
| 61 | Improving Drug-Therapy Decisions Through Educational Outreach | 1983 | 799 |
| 62 | The Conduct of in Vitro and in Vivo Drug-Drug Interaction Studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) Perspective. | 2003 | 792 |
| 63 | The Anticholinergic Risk Scale and Anticholinergic Adverse Effects in Older Persons | 2008 | 792 |
| 64 | Uncovering the Essential Genes of the Human Malaria Parasite Plasmodium falciparum by Saturation Mutagenesis | 2018 | 776 |
| 65 | Host-Directed Therapies for Bacterial and Viral Infections | 2018 | 775 |
| 66 | Mitochondrial Function as a Therapeutic Target in Heart Failure | 2017 | 773 |
| 67 | Dysfunctional HDL and Atherosclerotic Cardiovascular Disease | 2016 | 763 |
| 68 | Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model | 2015 | 758 |
| 69 | SGLT2 Inhibitors: Mechanisms of Cardiovascular Benefit Beyond Glycaemic Control | 2020 | 756 |
| 70 | SynergyFinder 3.0: An Interactive Analysis and Consensus Interpretation of Multi-Drug Synergies Across Multiple Samples | 2022 | 745 |
| 71 | Flucytosine: A Review of Its Pharmacology, Clinical Indications, Pharmacokinetics, Toxicity and Drug Interactions | 2000 | 743 |
| 72 | Nitric Oxide Signalling in Cardiovascular Health and Disease | 2018 | 736 |
| 73 | PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD | 2017 | 730 |
| 74 | Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference | 2012 | 729 |
| 75 | Medical Need, Scientific Opportunity and the Drive for Antimalarial Drugs | 2002 | 724 |
| 76 | Abdominal Aortic Aneurysm: Update on Pathogenesis and Medical Treatments | 2019 | 724 |
| 77 | Clinical Pharmacokinetics of Tacrolimus | 1995 | 721 |
| 78 | Herbal Medicinals: Selected Clinical Considerations Focusing on Known or Potential Drug-Herb Interactions | 1998 | 719 |
| 79 | DGIdb 3.0: A Redesign and Expansion of the Drug–Gene Interaction Database | 2018 | 713 |
| 80 | Quinolines and Structurally Related Heterocycles as Antimalarials | 2010 | 707 |
| 81 | The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer | 2005 | 698 |
| 82 | Pharmacokinetic Interactions With Rifampicin | 2003 | 697 |
| 83 | The Rising Tide of Polypharmacy and Drug-Drug Interactions: Population Database Analysis 1995–2010 | 2015 | 697 |
| 84 | The NLRP3 Inflammasome in Acute Myocardial Infarction | 2018 | 693 |
| 85 | Grapefruit Juice–Drug Interactions | 1998 | 688 |
| 86 | Drug Interactions at the GABA Receptor-Ionophore Complex. | 1982 | 686 |
| 87 | Expression of PD-L1, PD-L2, PD-1 and CTLA4 in Myelodysplastic Syndromes Is Enhanced by Treatment With Hypomethylating Agents | 2014 | 683 |
| 88 | Diuretic Therapy | 1998 | 677 |
| 89 | A Drug Burden Index to Define the Functional Burden of Medications in Older People | 2007 | 676 |
| 90 | N-Acetylcysteine—A Safe Antidote for Cysteine/Glutathione Deficiency | 2007 | 676 |
| 91 | Bile Acid Receptors as Targets for Drug Development | 2014 | 675 |
| 92 | Pharmacokinetics and Dosage Adjustment in Patients With Hepatic Dysfunction | 2008 | 669 |
| 93 | Arterial Thrombosis—Insidious, Unpredictable and Deadly | 2011 | 668 |
| 94 | A Phase 3 Study of Deferasirox (ICL670), a Once-Daily Oral Iron Chelator, in Patients With β-Thalassemia | 2006 | 666 |
| 95 | Artemisinin: Mechanisms of Action, Resistance and Toxicity | 2002 | 654 |
| 96 | Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation | 2003 | 653 |
| 97 | Methotrexate and Its Mechanisms of Action in Inflammatory Arthritis | 2020 | 652 |
| 98 | Cancer Immunotherapy — Immune Checkpoint Blockade and Associated Endocrinopathies | 2017 | 647 |
| 99 | Defective N-Oxidation of Sparteine in Man: A New Pharmacogenetic Defect | 1979 | 638 |
| 100 | Analysis of Combined Drug Effects: A New Look at a Very Old Problem | 1983 | 636 |